Arakis and Vectura announce start of phase IIb trial of NVA237 for COPD

19-Oct-2005

Arakis Ltd. , a wholly-owned subsidiary of Sosei Co. Ltd. , and Vectura Group plc announced that their collaborative product, NVA237 (formerly AD 237), a novel inhaled once daily treatment for chronic obstructive pulmonary disease (COPD), has entered a Phase IIb multiple dose-ranging clinical trial. NVA237 is being developed and commercialised by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol (QAB149), under the terms of the agreement signed in April 2005.

The study is a randomised, double-blind, multi-centre, placebo-controlled trial designed to evaluate the efficacy, safety and dose response of NVA237 in patients diagnosed with COPD over a four week period.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

The Crafoord Prize in Polyarthritis 2013

DDBST Dortmund Data Bank Software + Separation Technology GmbH - Oldenburg, Germany

DDBST Dortmund Data Bank Software + Separation Technology GmbH - Oldenburg, Germany

OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding

U.S. Food and Drug Administration (FDA) Approves Recombinant Protein Treatment for Tibia Fractures - Wyeth's rhBMP-2/ACS Offers Potential for Improved Fracture Healing

FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant - "These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"

FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant - "These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"

Amgen to Acquire Micromet - All-Cash Transaction Values Micromet at $1.16 Billion

Breast implants could become safer thanks to cell-friendly surface

The right messenger for a healthy immune response - Researchers from Helmholtz Center for Infection Research, Germany, decipher special role of the messenger Beta-interferon for immune responses

It takes 2 to infect - Structural biologists shed light on mechanism of invasion protein

AstraZeneca and Targacept: Global Collaboration and License Agreement for TC-5214 for the Treatment of Major Depressive Disorder

ScanBalt Campus - Coordinating Education and Research in ScanBalt BioRegion

QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension